egfr tyrosine kinase inhibitors in lung cancer: make no assumptions

Documenti analoghi

• Response to second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer: make no assumptions
  di: Karam, I., et al.
  Pubblicazione: (2012)
• A personalized approach to treatment: use of egfr tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada
  di: Hirsh, V., et al.
  Pubblicazione: (2012)
• Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
  di: Suda, Kenichi, et al.
  Pubblicazione: (2021)
• Targeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR?
  di: De Greve, Jacques, et al.
  Pubblicazione: (2020)
• Corrigendum: A personalized approach to treatment: use of egfr tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada
  di: Hirsh, V., et al.
  Pubblicazione: (2012)